

Alecensa® (alectinib) - New indication

- On April 18, 2024, <u>Genentech announced</u> the FDA approval of <u>Alecensa (alectinib)</u>, as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDAapproved test.
- Alecensa is also approved for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test.
- The approval of Alecensa for the new indication was based on a randomized, open-label study in 257 patients with resectable ALK-positive NSCLC. Patients were randomized to receive Alecensa or platinum-based chemotherapy following tumor resection. The major efficacy measures were disease-free survival (DFS) in patients with stage II-IIIA NSCLC and DFS in patients with stage IB-IIIA NSCLC (intent-to-treat [ITT] population).
 - In the stage II-IIIA population, median DFS was not reached with Alecensa vs. 44.4 months with chemotherapy (hazard ratio [HR] 0.24, 95% CI: 0.13, 0.45; p < 0.0001). In the ITT population, median DFS was not reached with Alecensa vs. 41.3 months with chemotherapy (HR 0.24, 95% CI: 0.13, 0.43; p < 0.0001).</p>
- The recommended dose of Alecensa for both of its uses is 600 mg orally twice daily. The duration
 of treatment for adjuvant treatment of resected NSCLC is a total of 2 years or until disease
 recurrence or unacceptable toxicity.
 - Refer to the Alecensa drug label for complete dosing recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.